Martin Kolev
Company: Apellis
Job title: Associate Director – Complement Science
Seminars:
Understanding the Increasing Use of Complement-Mediators as Combination Therapies to Expand Indications into Oncology, Autoimmunity & Beyond 11:00 am
Join this workshop to deepen your understanding of the complement-mediated combination therapies to work towards expansion beyond rare diseases. Discussing the precise molecular mechanisms where specific complement components drive immunosuppression within the tumour, exploring the signalling pathways involved Exploring the preclinical and emerging clinical data supporting the links between the complement and immune checkpoint pathways,…Read more
day: Pre-Conference Workshop Day
The Complement Advisory Board Fireside Chat: An Overview of the Complement Therapeutics Landscape 9:00 am
Discussing the dynamic landscape of complement drug development, exploring novel targets and diverse therapeutic modalities and their potential across various diseases, including kidney, CNS, and ophthalmology Addressing critical operational and clinical challenges in complement therapy, delivery, and oral formulations Focussing on the scientific and translational hurdles that remain, covering the importance of developing robust biomarkers,…Read more
day: Conference Day One
Harnessing Clinical Success in Complement-Mediated Kidney Diseases to Inform Wider Complement-Mediated Indications 9:30 am
Exploring the role of C3 fragments in the kidney in pathogenesis of C3G and other kidney disease Efficacy of C3/C3b inhibition in C3G patients Understanding the impact of C3/C3b inhibition on complement deposits in the kidney of C3G patientsRead more
day: Conference Day One
Panel Discussion: Navigating the Clinical Challenges as Complement Inhibitors are Applied to Larger Patient Populations 10:30 am
Discussing the critical considerations for managing systemic complement inhibition and minimizing off-target effects and infection risks in a diverse patient cohort Overcoming diagnostic and biomarker limitations to accurately identify which patients within larger populations will truly benefit from complement inhibition Exploring innovative drug delivery modalities are essential to improve patient convenience and adherence for chronic…Read more
day: Conference Day One